NCT07110454 Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
| NCT ID | NCT07110454 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Epiminder America, Inc. |
| Condition | Epilepsy |
| Study Type | OBSERVATIONAL |
| Enrollment | 210 participants |
| Start Date | 2026-06 |
| Primary Completion | 2029-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 210 participants in total. It began in 2026-06 with a primary completion date of 2029-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to address the challenges of correctly monitoring, managing, and diagnosing epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who cannot use or are not able to use more standard monitoring techniques. This research is being done to understand how the Minder System helps physicians make decisions about participant's epilepsy treatment after an actionable event. The Minder System was granted De Novo classification by the U.S. Food and Drug Administration (FDA) and is not investigational. Participants that have completed the DETECT study and received the Minder System previously will consent to join this long-term follow-up observational study. The study will collect information about general wellbeing, use of healthcare services, and experience using the Minder data over time to support long-term epilepsy care. All participants will continue to be followed by their treating physician and undergo assessments and visits every six (6) months until two (2) years after receiving the Minder device.
Eligibility Criteria
Inclusion Criteria: * Participant met all inclusion criteria, was enrolled in the DETECT study, and received the Minder device * Participant completed the DETECT study by receiving an actionable event or by completing the 6-month follow-up visit * Participant continues to have the Minder device implanted * Participant must continue to meet relevant DETECT study inclusion criteria Exclusion Criteria: * Participant meets any relevant DETECT study exclusion criteria including needing treatments or assessments that are not indicated with the Minder System like Magnetic Resonance Imaging (MRI)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07110454 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07110454 currently recruiting?
Yes, NCT07110454 is actively recruiting participants. Contact the research team at clinical@epiminder.com for enrollment information.
Where is the NCT07110454 trial being conducted?
This trial is being conducted at Phoenix, United States, Palo Alto, United States, New Haven, United States, Jacksonville, United States and 8 additional locations.
Who is sponsoring the NCT07110454 clinical trial?
NCT07110454 is sponsored by Epiminder America, Inc.. The trial plans to enroll 210 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.